97. Ulcerative colitis Clinical trials / Disease details


Clinical trials : 2,527 Drugs : 1,465 - (DrugBank : 259) / Drug target genes : 144 - Drug target pathways : 202

  
7 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT05088369
(ClinicalTrials.gov)
November 202112/10/2021Assessment of the Safety, Tolerability, and Pharmacokinetic of HM201A First-in-human, Double-blind, Placebo-controlled, Phase 1 Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Intravenous Doses of HM201 (Pegylated Human Adrenomedullin) in Healthy Subjects (Adults)Ulcerative Colitis;Crohn's DiseaseDrug: HM201;Drug: PlaceboSyneos HealthHimuka AM Pharma Corp.Not yet recruiting18 Years55 YearsAll68Early Phase 1NULL
2NCT03581149
(ClinicalTrials.gov)
March 26, 201827/3/2018Tolerability and Efficacy of Sodium Picosulfate/Magnesium Citrate Versus PEG/Ascorbic Acid in Ulcerative Colitis PatientsTolerability and Efficacy of Low-Volume Sodium Picosulfate/Magnesium Citrate Versus 2L Polyethylene Glycol/Ascorbic Acid in Patients With Ulcerative Colitis Undergoing Colonoscopy: A Randomized Controlled TrialUlcerative ColitisDrug: Sodium Picosulfate/Magnesium Citrate Laxative;Drug: 2L polyethylene glycol/ascorbic acidAmerican University of Beirut Medical CenterNULLRecruiting18 Years65 YearsAll68Phase 4Lebanon
3JPRN-UMIN000013892
2013/07/0106/05/2014A prospective randomized controlled trial of AJG522 versus standard PEG plus E as bowel preparation for colonoscopy Ulcerative colitis and so onAJG522
PEG plus E (Niflec®)
Gunma University Graduate School of MedicineNULLComplete: follow-up complete20years-oldNot applicableMale and Female80Phase 4Japan
4NCT02073526
(ClinicalTrials.gov)
May 20139/1/2014Anti-TNF-alpha Trough Level Measurements in Inflammatory Bowel DiseaseAnti-TNF-alpha Trough Level Measurements in Inflammatory Bowel DiseaseInflammatory Bowel Disease;Crohn's Disease;Ulcerative ColitisDrug: Infliximab, adalimumab, certolizumab pegolOslo University HospitalNULLCompleted18 YearsN/ABoth1230N/ANorway
5EUCTR2010-020448-37-NL
(EUCTR)
21/12/201116/09/2010Randomized placebo-controlled multicenter exploratory Phase IIA study to assess the safety and efficacy of PEG-liposomal prednisolone sodium phosphate (Nanocort) in subjects with active ulcerative colitis.Randomized placebo-controlled multicenter exploratory Phase IIA study to assess the safety and efficacy of PEG-liposomal prednisolone sodium phosphate (Nanocort) in subjects with active ulcerative colitis. Active Ulcerative Colitis
MedDRA version: 14.1;Level: LLT;Classification code 10045365;Term: Ulcerative colitis;System Organ Class: 10017947 - Gastrointestinal disorders;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
Product Name: PEG-liposomal prednisolone sodium phosphate
Product Code: Nanocort
INN or Proposed INN: Prednisolone Sodium Phosphate
Other descriptive name: PREDNISOLONE SODIUM PHOSPHATE
Enceladus PharmaceuticalsNULLNot RecruitingFemale: yes
Male: yes
20Phase 2Belgium;Netherlands
6EUCTR2010-020448-37-BE
(EUCTR)
10/12/201022/12/2010Randomized placebo-controlled multicenter exploratory Phase IIA study to assess the safety and efficacy of PEG-liposomal prednisolone sodium phosphate (Nanocort) in subjects with active ulcerative colitis.Randomized placebo-controlled multicenter exploratory Phase IIA study to assess the safety and efficacy of PEG-liposomal prednisolone sodium phosphate (Nanocort) in subjects with active ulcerative colitis. Active Ulcerative Colitis
MedDRA version: 14.1;Level: LLT;Classification code 10045365;Term: Ulcerative colitis;System Organ Class: 10017947 - Gastrointestinal disorders;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
Product Name: PEG-liposomal prednisolone sodium phosphate
Product Code: Nanocort
INN or Proposed INN: Prednisolone Sodium Phosphate
Other descriptive name: PREDNISOLONE SODIUM PHOSPHATE
Enceladus PharmaceuticalsNULLNot RecruitingFemale: yes
Male: yes
20Phase 2Belgium;Netherlands
7NCT01090154
(ClinicalTrials.gov)
December 1, 201015/3/2010Certolizumab Pegol for the Treatment of Moderate to Severe Ulcerative Colitis: An Open Label StudyCertolizumab Pegol for the Treatment of Moderate to Severe Ulcerative Colitis: An Open Label StudyUlcerative ColitisDrug: CimziaUniversity of WashingtonUCB Pharma;University of PennsylvaniaCompleted18 Years75 YearsAll27Phase 2United States